Skip to main content
Fig. 3 | Trials

Fig. 3

From: Efficacy and safety of exogenous ketone bodies for preventive treatment of migraine: A study protocol for a single-centred, randomised, placebo-controlled, double-blind crossover trial

Fig. 3

Sensitivity of sample size with regard to expected difference in reduction in number of migraine days per 4 weeks of IMP compared to placebo. Example given, based on an effect size of 2 and a statistical power of 90%. The curves are smoothed and are for illustrative purposes only

Back to article page

Trials

ISSN: 1745-6215